If you have a type of cancer called acute myeloid leukemia (AML), your healthcare provider may prescribe Tabloid. This medication is available as a tablet that is taken once or twice a day; your exact dosage will be based on your height, weight, and various other factors. Side effects can include infections, bleeding, and anemia.
Tabloid® (thioguanine) is a prescription medication approved for the treatment of acute nonlymphocytic leukemia, a type of cancer of the blood and bone marrow. Acute nonlymphocytic leukemia is more commonly known as acute myeloid leukemia, or acute myelogenous leukemia (AML). Tabloid is normally given as part of a combination treatment that includes other medicines.
Tabloid belongs to a group of medicines called purine analogs. The active ingredient in the medication is thioguanine. Healthcare providers may also refer to it as 6-thioguanine, or simply TG.
Tabloid is made by DSM Pharmaceuticals, Inc., for GlaxoSmithKline.
In studies, Tabloid has been shown to help people with AML achieve remission when used as part of combination treatment. In one study, 59 percent of children with AML who had not been previously treated went into remission when given Tabloid in combination with other medicines, including prednisone, cytarabine (DepoCyt®), cyclophosphamide (Cytoxan®), and vincristine (Vincasar PFS®). The children stayed in remission for about 11.5 months.
In another study, 53 percent of adults with AML who had not received previous treatment achieved remission when given Tabloid in combination with cytarabine. Remission lasted about 8.8 months.